Unibest

Pharmaceutical intermediates

Semaglutide Intermediates

3 pharmaceutical intermediates for Semaglutide. Indication: Diabetes Mellitus, Type 2; Overweight.

Submit a ProjectAll intermediates

About Semaglutide

Originator
Novo Nordisk Inc
Indication
Diabetes Mellitus, Type 2; Overweight
Approved Date
09/20/2019
DS/DP
03/20/2026

Available intermediates

3 intermediates currently listed for Semaglutide. Request specifications, documentation or a quotation for any item below.

Semaglutide intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
AEEA-HCl134979-01-4//
AEEA-AEEA1143516-05-5//
Boc-AEEA-AEEA1069067-08-8//

Other programs under S

SaracatinibSarecycline HydrochlorideSarolanerSaxagliptinSeladelparSeltorexantSitafloxacin hydrate Sofosbuvir

Building toward Semaglutide?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

Submit a Project Talk to the team

How can we help you?

Receive insights into the latest events and regulatory updates

Sent directly to your email

Get industry insights and Unibest news here

Contact Us →